Showing results (711-720 of 1,794) with videos related to

Sort By:
Pageof 180
Mabs|May 27, 2026
Prediction of antibody non-specificity using protein language models and biophysical parametersLaila I Sakhnini, Ludovica Beltrame, Simone Fulle, et al.
Mabs|May 19, 2026
Novel bispecific T-cell engagers overcoming acquired EGFR resistanceLennart Kühl, Ann-Kathrin Löffler, Oliver Seifert, et al.
Mabs|June 8, 2026
Subcutaneous drug delivery of high concentration antibody products - part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentationsIndrajit Ghosh, Suyash Deodhar, Hiten Gutka, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
Mabs|May 10, 2026
Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safetyMatthew Siegel, Eric Zhu, Daniel Rios, et al.
Mabs|May 23, 2025
Process development for production of non-originator NISTmAb from CHO and NS0 cell linesErica J Fratz-Berilla, Nicole Azer, Xin Bush, et al.
Mabs|April 28, 2026
Engineering of acidic pH-responsive anti-CD3 binding antibodiesGrégory La Sala, Katharina B Kroell, Mudita Pincha, et al.
Mabs|April 28, 2026
Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implicationsShiqi Yang, Takahiro Anzai, Ryo Tsumura, et al.
Mabs|May 7, 2026
A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodiesLihua Shi, Minseon Cho, Motohiko Nishida, et al.
Mabs|March 11, 2017
Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodiesRong Yang, Tushar Jain, Heather Lynaugh, et al.
Pageof 180